Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−2.35 EUR
−398.86 M EUR
1.66 B EUR
127.97 M
About Alnylam Pharmaceuticals, Inc.
Sector
CEO
Yvonne L. Greenstreet
Headquarters
Cambridge
Website
Founded
2002
FIGI
BBG000Q4XDD3
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002 and is headquartered in Cambridge, MA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
ALNY5653584
Alnylam Pharmaceuticals, Inc. 1.0% 15-SEP-2027Yield to maturity
−1.46%
Maturity date
Sep 15, 2027
Explore more bonds
Curated watchlists where DUL is featured.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on MUN exchange ALNYLAM PHARMACE.DL-,0001 stocks are traded under the ticker DUL.
We've gathered analysts' opinions on ALNYLAM PHARMACE.DL-,0001 future price: according to them, DUL price has a max estimate of 370.24 EUR and a min estimate of 164.76 EUR. Watch DUL chart and read a more detailed ALNYLAM PHARMACE.DL-,0001 stock forecast: see what analysts think of ALNYLAM PHARMACE.DL-,0001 and suggest that you do with its stocks.
Yes, you can track ALNYLAM PHARMACE.DL-,0001 financials in yearly and quarterly reports right on TradingView.
ALNYLAM PHARMACE.DL-,0001 is going to release the next earnings report on Feb 6, 2025. Keep track of upcoming events with our Earnings Calendar.
DUL earnings for the last quarter are −0.78 EUR per share, whereas the estimation was −0.82 EUR resulting in a 5.09% surprise. The estimated earnings for the next quarter are −0.56 EUR per share. See more details about ALNYLAM PHARMACE.DL-,0001 earnings.
ALNYLAM PHARMACE.DL-,0001 revenue for the last quarter amounts to 449.90 M EUR, despite the estimated figure of 478.63 M EUR. In the next quarter, revenue is expected to reach 550.44 M EUR.
DUL net income for the last quarter is −100.21 M EUR, while the quarter before that showed −15.77 M EUR of net income which accounts for −535.52% change. Track more ALNYLAM PHARMACE.DL-,0001 financial stats to get the full picture.
No, DUL doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 17, 2024, the company has 2.10 K employees. See our rating of the largest employees — is ALNYLAM PHARMACE.DL-,0001 on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ALNYLAM PHARMACE.DL-,0001 EBITDA is −118.69 M EUR, and current EBITDA margin is −12.48%. See more stats in ALNYLAM PHARMACE.DL-,0001 financial statements.
Like other stocks, DUL shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ALNYLAM PHARMACE.DL-,0001 stock right from TradingView charts — choose your broker and connect to your account.